Showing 3261-3270 of 5662 results for "".
- Paradigm Shift: Cancer Patients Can Now Use Skin Creams During Radiation Therapyhttps://practicaldermatology.com/news/paradigm-shift-cancer-patients-can-now-use-skin-creams-during-radiation-therapy/2457556/Contrary to the advice most cancer patients receive when they go through radiation treatment, topical skin treatments, unless applied very heavily, do not increase the radiation dose to the skin and can be used in moderation before daily radiation treatments, according to a new study from the
- Injectable Methotrexate Product Now Availablehttps://practicaldermatology.com/news/20140117-injectable_methotrexate_product_now_available/2459369/For patients who do not tolerate oral methotrexate for psoriasis, a new recently approved injectable methotrexate product is now available from Antares Pharma. Approved in October 2013 for the subcutaneous methotrexate product for once weekly self-administration, Otrexup is indicated for use in adul
- Some Patients Apply Sunscreen to Nevi Onlyhttps://practicaldermatology.com/news/20130225-some_patients_apply_sunscreen_to_nevi_only/2459610/An unexpected number of patients with nevi report that they selectively apply sunscreens to moles only, and almost half of them say that a dermatologist told them to do so, according to a new study. (J Eur Acad Dermatol Venereol. e-pub). Of 1,816 European subjects surveyed (59.3% females, age 14-90
- Venous Thromboembolism Risk Lower in AD Patients: Analysishttps://practicaldermatology.com/news/venous-thromboembolism-risk-lower-in-ad-patients-analysis/2462196/A retrospective, observational analysis in the Journal of the American Academy of Dermatology showed that patients with atopic dermatitis (AD) do not have an increased risk for venous thromboembolism (VTE) compared with other immune-mediated inflammatory diseases. The ana
- Osteopontin Potently Stimulates Hair Follicle Stem Cells for Robust Hair Growthhttps://practicaldermatology.com/news/osteopontin-potently-stimulates-hair-follicle-stem-cells-for-robust-hair-growth/2461802/Do hairy moles hold the secret to understanding hair growth? Maybe, according to research published in the June 21, 2023 issue of Nature. Using a mouse model, researchers tracked the activity of ha
- Survey: Social Media Isn’t All That Helpful for Growing Your Derm Practicehttps://practicaldermatology.com/news/survey-social-media-isnt-all-that-helpful-for-growing-your-derm-practice/2460384/Patients often do not take social media into consideration when looking for a dermatologist, according to a survey from researchers at the George Washington University. The survey appears in the Journal of Drugs in Derma
- Dersimelagon Improves Sunlight Tolerance in EPP and XLPhttps://practicaldermatology.com/news/dersimelagon-improves-sunlight-tolerance-in-epp-and-xlp/2486452/Dersimelagon, an oral melanocortin 1 receptor (MC1R) agonist, significantly improved sunlight tolerance in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), according to Phase 3 INSPIRE trial results presented by Amy Dickey Yeung, MD, at the American Academy of
- Dermatology Residents Show Gains After Targeted Topical Formulation Educationhttps://practicaldermatology.com/news/dermatology-residents-show-gains-after-targeted-topical-formulation-education/2486095/A small survey-based study found that dermatology residents from 3 training programs reported limited formal education in topical vehicle formulation science, but showed improved comfort, confidence, and knowledge after a targeted educational intervention.
- Reduced-Dose Tralokinumab Maintains Symptom Control for Up to 1 Year in Atopic Dermatitishttps://practicaldermatology.com/news/reduced-dose-tralokinumab-maintains-symptom-control-for-up-to-1-year-in-atopic-dermatitis/2485613/Adults with moderate-to-severe atopic dermatitis (AD) who achieved initial disease control with tralokinumab maintained improvements in symptoms and quality of life for up to 1 year following reduced dosing, according to a South Beach Symposium poster from April
- TOGETHER-PsA: Weight Loss Plus PsA Control with Ixekizumab and Tirzepatidehttps://practicaldermatology.com/news/together-psa-weight-loss-plus-psa-control-with-ixekizumab-and-tirzepatide/2485259/In the phase 3b TOGETHER-PsA trial, ixekizumab (Taltz, Eli Lilly) used in combination with tirzepatide (Zepbound, Eli Lilly) was more effective than ixekizumab monotherapy in adults with active psoriatic arthritis (PsA) who also have obesity or are overweight with a